Related Experiment Video
Updated: Apr 26, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
15.9K
Central effects of fingolimod
Vítor T Cruz1, Joaquim Fonseca
1Centro Hospitalar de Entre o Douro e Vouga, E.P.E, Santa Maria da Feira, Portugal.
Revista De Neurologia
|July 18, 2014
Summary
Fingolimod, an oral therapy for multiple sclerosis, works by modulating sphingosine-1-phosphate receptors. It not only reduces T cell entry into the CNS but also offers direct neuroprotection within the brain.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Fingolimod is the first oral therapy for relapsing-remitting multiple sclerosis (MS).
- It acts by modulating sphingosine-1-phosphate (S1P) receptors, specifically S1P1, on lymphocytes.
- This mechanism prevents T cell migration to the central nervous system (CNS) and suggests potential direct neuroprotective effects.
Purpose of the Study:
- To review existing data on the central nervous system (CNS) effects of fingolimod.
- To explore fingolimod's direct impact on CNS cells and its therapeutic potential beyond immunomodulation.
Main Methods:
- Review of clinical trial data and scientific literature on fingolimod's mechanism of action.
- Analysis of fingolimod's interaction with S1P receptors on various CNS cell types.
- Evaluation of evidence for direct neuroprotective and regenerative effects within the CNS.
Main Results:
- Fingolimod readily crosses the blood-brain barrier.
- It interacts with S1P receptors on oligodendrocytes, astrocytes, microglia, and neurons.
- These interactions promote remyelination, neuroprotection, and endogenous repair processes.
Conclusions:
- Fingolimod's efficacy in MS is attributed to its dual action: immunomodulation and direct modulation of S1P receptors in the CNS.
- Emerging evidence supports fingolimod's neuroprotective role in various models.
- Potential therapeutic applications are expanding to include neurodegenerative diseases and other CNS conditions.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
745
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
689
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
689
01:29Therapeutic Drug Monitoring: Affecting Factors
428
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
428
01:20Myasthenia Gravis: Overview and Treatment
3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
01:19Multiple Sclerosis l: Introduction
16
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16